PaulBChapmanMD

Attending Physician, Memorial Sloan Kettering Cancer Center. Professor of Medicine, Cornell University-Weill Medical College

Request Appointment

Overview of Dr. Chapman

Dr. Paul Chapman is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, NewYork-Presbyterian Brooklyn Methodist Hospital, Memorial Sloan Kettering Cancer Center, Memorial Hospital for Cancer and allied Diseases, Memorial Hospital for Cancer and allied Diseases, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Weill Cornell Medicine and has been in practice 36 years. Dr. Chapman accepts several types of health insurance, listed below. He is one of 464 doctors at Memorial Sloan Kettering Cancer Center and one of 88 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
1305 York Ave.
12th Floor
New York, NY 10065
Book by Phone+1(520) 487-4409
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterImmunology, 1984 - 1988
University of ChicagoResidency, Internal Medicine, 1981 - 1984
Weill Cornell MedicineClass of 1981

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 1988 - 2024
IL State Medical License 1981 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 1997 Nov 01
Completed
Phase 2
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma Start of enrollment: 1998 May 01
Completed
Phase 2
Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2004 Mar 01
Withdrawn
Phase 2
Tanespimycin in Treating Patients With Stage III-IV Melanoma Start of enrollment: 2004 Jun 01
Terminated
Phase 2
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma Start of enrollment: 2007 Mar 01
Completed
Phase 2
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Apr 01
Completed
Phase 2
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection Start of enrollment: 2005 Sep 01
Completed
Phase 2
Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma Start of enrollment: 2005 Jan 01
Completed
Phase 2
Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma Start of enrollment: 2007 Dec 01
Completed
Not Applicable
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2009 Mar 01
Completed
Phase 2
Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma Start of enrollment: 2009 Apr 01
Completed
Phase 2
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation Start of enrollment: 2011 Nov 01
Terminated
Phase 2
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation Start of enrollment: 2012 Sep 01
Completed
Phase 2
BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation Start of enrollment: 2013 Jul 01
Completed
Phase 2
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Start of enrollment: 2014 May 01
Completed
Phase 2
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma Start of enrollment: 2014 Apr 09
Completed
Phase 2
Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma Start of enrollment: 2017 May 16
Completed
Phase 1
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery Start of enrollment: 2019 Feb 14
Completed
Join now to see all

Publications & Presentations

PubMed

4 citations
Management of immune-related cutaneous adverse events with dupilumab.
Alyce Mei-Shiuan Kuo, Stephanie Gu, Joseph Stoll, Andrea P Moy, Stephen W Dusza, Allison Gordon, Elena C Haliasos, Yelena Janjigian, Lukas Kraehenbuehl, Elizabeth A Qu...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.
Kimberly Loo, Hannah L Kalvin, Katherine S Panageas, Margaret K Callahan, Paul B Chapman, Parisa Momtaz, Alexander N Shoushtari, Michael A Postow, Allison Betof Warner...> ;Pigment Cell & Melanoma Research. 2023 Apr 11
4 citations
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
Thomas M Atkinson, Jennifer L Hay, Soo Young Kim, Elizabeth Schofield, Michael A Postow, Parisa Momtaz, Allison Betof Warner, Alexander N Shoushtari, Margaret K Callah...> ;The Oncologist. 2023 Apr 6
5 citations
PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.
Margaret K Callahan, Paul B Chapman> ;Journal of Clinical Oncology. 2022 May 1
24 citations
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
Michael A Postow, Debra A Goldman, Alexander N Shoushtari, Allison Betof Warner, Margaret K Callahan, Parisa Momtaz, James W Smithy, Ellesa Naito, Marina K Cugliari, V...> ;Journal of Clinical Oncology. 2022 Apr 1
17 citations
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translatio...
Friedman, C., Spencer, C., Cabanski, C., Panageas, K., Wells, D., Ribas, A., Tawbi, H., Tsai, K., Postow, M., Shoushtari, A., Chapman, P., Karakunnel, J., Bucktrout, S...> ;Journal for Immunotherapy of Cancer. 2022 Jan 1
7 citations
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
Paul B. Chapman, Vetri Sudar Jayaprakasam, Katherine S. Panageas, Margaret K. Callahan, Michael A. Postow, Alexander N. Shoushtari, Allison Betof Warner> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
48 citations
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.
, , , , , , , , , , , , , , , , , , , , , , > ;Science Translational Medicine. 2021 Aug 25
2 citations
Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.
Paul B. Chapman> ;Journal of Clinical Oncology. 2021 Jun 4
11 citations
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
F. Stephen Hodi, Paul B. Chapman, Mario Sznol, Christopher D. Lao, Rene Gonzalez, Michael Smylie, Gregory A. Daniels, John A. Thompson, Ragini R. Kudchadkar, William H...> ;Melanoma Research. 2021 Feb 1
21 citations
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
Alexander N. Shoushtari, Walid K. Chatila, Arshi Arora, Francisco Sanchez-Vega, Havish S. Kantheti, Jorge A. Rojas Zamalloa, Penina Krieger, Margaret K. Callahan, Alli...> ;Clinical Cancer Research. 2021 Jan 28
38 citations
The State of Melanoma: Emergent Challenges and Opportunities.
Michael B. Atkins, Clara Curiel-Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre-Ghiso, Maria S. Soengas, Ashani T. Weeraratna, Keith T. ...> ;Clinical Cancer Research. 2021 Jan 7
6 citations
Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
James W. Smithy, Matthew J. Pianko, Colleen Maher, Michael A. Postow, Alexander N. Shoushtari, Parisa Momtaz, Paul B. Chapman, Jae H. Park, Margaret K. Callahan> ;Journal of Immunotherapy. 2021 Jan 1
6 citations
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas.
Alvin Makohon-Moore, Evan J. Lipson, Jody E. Hooper, Amanda Zucker, Jungeui Hong, Craig M. Bielski, Akimasa Hayashi, Collin Tokheim, Priscilla Baez, Rajya Kappagantula...> ;Clinical Cancer Research. 2021 Mar 1
19 citations
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
, , , , , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2020 Jul 1
20 citations
Immune Checkpoint Inhibitor-Associated Optic Neuritis.
Jasmine H. Francis, Korey Jaben, Bianca Santomasso, Julia Canestraro, David H. Abramson, Paul B. Chapman, Meghan Berkenstock, Mary E. Aronow> ;Ophthalmology. 2020 May 8
36 citations
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Danielle M. Bello, Katherine S. Panageas, Travis J. Hollmann, Alexander N. Shoushtari, Parisa Momtaz, Paul B. Chapman, Michael A. Postow, Margaret K. Callahan, Mary S....> ;Annals of Surgical Oncology. 2020 Apr 1
121 citations
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
Allison Betof Warner, Jessica S. Palmer, Alexander N. Shoushtari, Debra A. Goldman, Katherine S. Panageas, Sara A. Hayes, Raazi Bajwa, Parisa Momtaz, Margaret K. Calla...> ;Journal of Clinical Oncology. 2020 Feb 13
42 citations
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Axel Hauschild, Paolo A. Ascierto, Dirk Schadendorf, Jean-Jacques Grob, Antoni Ribas, Felix Kiecker, Caroline Dutriaux, Lev V. Demidov, Céleste Lebbé, Piotr Rutkowski,...> ;European Journal of Cancer. 2020 Jan 1
8 citations
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
Marjorie G. Zauderer, Gowtham Jayakumaran, Mariel A. DuBoff, Liying Zhang, Jasmine H. Francis, David H. Abramson, Andrea Cercek, Garrett M. Nash, Alexander N. Shoushta...> ;Journal of Thoracic Oncology. 2019 Nov 1
125 citations
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S. Phillips, Jennifer Wu, Matthew D. Hellmann, Michael A. Postow, Naiyer A. Rizvi, Azael Freites-Martinez, Donald Chan, Stephen W. Dusza, Robert J. Motzer, Jon...> ;Journal of Clinical Oncology. 2019 Jun 19
25 citations
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.
Katherine Lee Chuy, Evangelos Oikonomou, Michael A. Postow, Margaret K. Callahan, Paul B. Chapman, Alexander N. Shoushtari, Tomas G. Neilan, Michael G. Fradley, Lakshm...> ;The Oncologist. 2019 May 1
1 citations
Chemoreduction of Orbital Recurrence of Uveal Melanoma by Intra-Arterial Melphalan.
Jasmine H. Francis, Christopher A. Barker, Vivian T. Yin, Richard D. Carvajal, Paul B. Chapman, David H. Abramson, Y. Pierre Gobin> ;Ocular Oncology and Pathology. 2019 Apr 1
27 citations
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAFV600-mutated Metastatic Melanoma.
Yibing Yan, Matthew Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen S...> ;Clinical Cancer Research. 2019 Mar 1
59 citations
Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer
Craig M. Bielski, Mark T.A. Donoghue, Mayur Gadiya, Aphrothiti J. Hanrahan, Helen Won, Matthew T. Chang, Philip Jonsson, Alexander V Penson, Alexander N. Gorelick, Chr...> ;Cancer Cell. 2018 Nov 12
Join now to see all

Press Mentions

Time's up for Anti-PD-1/L1 plus Targeted Therapy in BRAF MelanomaJanuary 26th, 2022
Merck’s Proposed Less Frequent Keytruda Dosing May Allow for Minor Uptake BoostNovember 19th, 2019
Dr. Paul Chapman on the Choice to Pursue Adjuvant Immunotherapy for Melanoma PatientsJune 19th, 2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

New York-Presbyterian HospitalNew York, New York
NewYork-Presbyterian Brooklyn Methodist HospitalBrooklyn, New York
Memorial Sloan Kettering Cancer CenterNew York, New York
Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey
Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey
Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Health Alliance PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Wellmark Alliance Select
Please verify your coverage with the provider's office directly when scheduling an appointment